ICON Plc - Company Profile
Powered by 
All the data and insights you need on ICON Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date ICON Plc Strategy Report
- Understand ICON Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
ICON Plc Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of ICON Plc Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 24 Nov 2022 | Lorem |
| Nectin Therapeutics engages with CRO ICON for Phase I trial of solid tumor candidate | 08 Mar 2022 | William Newton |
| Rational Vaccines in CRO talks for Phase I/II therapeutic herpes vaccine trial, ICON is ‘frontrunner’; eyes USD 30–60m Series B by 3Q22 | 28 Jan 2022 | William Newton |
| Vaxart engaged with CRO Icon for Phase II trial of COVID-19 vaccine tablet | 11 Nov 2021 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer